Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc has demonstrated a positive financial trajectory, with third-quarter revenue exceeding consensus expectations and management raising gross margin guidance for 2025 to 76-77%, indicating a strong outlook for profitability. The company's commitment to a strategic approach in light adjustable lens (LAL) placements is expected to enhance utilization rates across an expanding installed base, which supports sustained double-digit growth. Additionally, despite increased operating expenses, RxSight's proactive management indicates confidence in achieving operational efficiency and financial performance improvements moving forward.

Bears say

RxSight Inc has experienced a significant decline in its operational metrics, with monthly utilization of light adjustable lenses (LALs) decreasing to 8.0 units per laser delivery device (LDD) in 3Q25, down from 8.7 in the preceding quarter and 10.1 a year prior. The company reported revenue of $30.3 million for the period, reflecting a 14% year-over-year decrease, alongside a sharp decline in LDD placements which fell by 68% year-over-year and 38% quarter-over-quarter to just 25 units in 2Q25. Additional risks impacting the company's outlook include limited market adoption due to the need for specialized capital equipment, challenges in commercial execution, increasing competition within the intraocular lens market, and potential financing that could dilute shareholder value.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.